Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellumen, Mitsubishi Tanabe Enter Tox Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cellumen, Mitsubishi Tanabe Enter Tox Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellumen, Inc., a discovery toxicology company, entered an agreement with Mitsubishi Tanabe Pharma Corp. (MTPC), to develop panels of biomarkers that identify toxicity early in the drug development process.
   
“We’re pleased to announce this collaboration with MTPC,” says D. Lansing Taylor, Ph.D., chief executive of Cellumen. “By working together to develop biomarker panels, we hope to identify toxic liabilities much earlier in the drug development process than currently exists in the marketplace. Our ultimate goal is to enable MTPC to prioritize its lead drug series.”
   
Cellumen’s CellCiphr CSB Toxicity Profiling Services can identify toxic compounds in late primary screening through early preclinical phases, before entering expensive pre-clinical testing. By integrating optimal cells, panels of functional biomarkers and classifier software, CellCiphr is able to create a Safety Risk Index for compounds, and help researchers predict potential rodent or human toxicity earlier in the process.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics